VIMEX ENDOSCOPY is one of few world-wide original manufacturers of rigid endoscopy devices like video endoscopy systems, light sources, arthroscopy shavers and medical fluid pumps. During the first years of its activity, the Company was manufacturing medical devices sold under different brands around the world. Due to the quality of its products, VIMEX has reached a high recognition on the market and become one of the most respected European OEM manufacturers in the world. Medical equipment manufactured in Gliwice, Poland are successfully used in many European countries (mainly in Germany and Switzerland), in Asia, Africa and Latin America. Every year VIMEX ENDOSCOPY devices find their recognition on the largest international medical trade fairs, such as Medica in Germany or Arab Health in Dubai, UAE. To ensure the highest quality of its products and their compliance with legal requirements, the Company has implemented ISO 9001 and ISO 13485 systems for designing and manufacturing medical equipment. All VIMEX ENDOSOCPY devices are CE marked.
25.11.Z - Manufacture of metal structures and parts of structures
25.61.Z - Treatment and coating of metals
25.62.Z - Mechanical working of metal elements
25.99.Z - Manufacture of other fabricated metal products not elsewhere classified
26.60.Z - Manufacture of irradiation, electromedical and electrotherapeutic equipment
32.50.Z - Manufacture of medical and dental instruments and supplies
46.46.Z - Wholesale of pharmaceutical goods
71.20.B - Other technical testing and analysis
72.19.Z - Other research and experimental development on natural sciences and engineering
78.20.Z - Temporary employment agency activities
2017 | 2018 | 2019 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Net sales | 14,8 | 16,6 | 18,3 | 10,8 |
Liabilities and provisions | 2,3 | 2,7 | 3,3 | 23,3 |
Equity | 1,4 | 1,9 | 2,1 | 10,6 |
Total assets | 3,7 | 4,6 | 5,4 | 18 |
Cash and cash equivalents | 0,4 | 0,6 | 1 | 61 |
Depreciation | 0,3 | 0,4 | 0,5 | 32 |
Gross profit / loss | 0,6 | 0,6 | 0,3 | -50,7 |
EBITDA | 1 | 1 | 0,9 | -13,9 |
Net profit / loss | 0,5 | 0,5 | 0,2 | -57,2 |
Operating profit (EBIT) | 0,7 | 0,6 | 0,4 | -41 |
Current assets | 2,8 | 3,8 | 5 | 32,4 |
% | % | % | p.p. | |
Return on equity (ROE) | 36,3 | 25,2 | 9,7 | -15,5 |
Return on sales (ROS) | 3,5 | 2,9 | 1,1 | -1,8 |
Equity ratio | 38,3 | 41,5 | 38,9 | -2,6 |
EBITDA margin | 7,1 | 6,2 | 4,8 | -1,4 |
Gross profit margin | 4,3 | 3,6 | 1,6 | -2 |
Days | Days | Days | Days | |
Current liabilities turnover ratio | 50 | 56 | 47 | -9 |
Current ratio | 1,3 | 1,4 | 1,6 | 0,2 |
Net debt to EBITDA | 0,6 | 0,4 | 0,4 | 0 |
Opinions regarding services, products, and company activities are not verified. This means that ING Services for Business S.A., as the provider of the Aleo platform, does not ensure that the published opinions come from consumers who have used the product or availed of the company's services. However, we do strive to ensure that opinions do not violate universally applicable laws.